MARKET

ITCI

ITCI

Intra-Cellular Therapies
NASDAQ
131.25
+0.01
+0.01%
Pre Market: 131.17 -0.08 -0.06% 04:23 03/11 EDT
OPEN
131.21
PREV CLOSE
131.24
HIGH
131.28
LOW
131.20
VOLUME
1
TURNOVER
0
52 WEEK HIGH
131.36
52 WEEK LOW
63.30
MARKET CAP
13.96B
P/E (TTM)
-181.2595
1D
5D
1M
3M
1Y
5Y
1D
10 overbought stocks to watch as Wall Street sinks, signaling potential pullbacks
Seeking Alpha · 21h ago
Weekly Report: what happened at ITCI last week (0303-0307)?
Weekly Report · 1d ago
Adobe, DICK's Sporting Goods, Dollar General To Report Results As Investors Look To Inflation Report
Seeking Alpha · 2d ago
JNJ Halts Development of Depression Drug Over Efficacy Concerns
NASDAQ · 3d ago
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'
Benzinga · 3d ago
Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition
Seeking Alpha · 5d ago
TimesSquare U.S. Small Cap Growth Strategy Q4 2024 Commentary
Seeking Alpha · 6d ago
Weekly Report: what happened at ITCI last week (0224-0228)?
Weekly Report · 03/03 09:25
More
About ITCI
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

Webull offers Intra-Cellular Therapies Inc stock information, including NASDAQ: ITCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITCI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ITCI stock methods without spending real money on the virtual paper trading platform.